NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: HeartBeam Inc. (NASDAQ: BEAT) Receives Buy Rating and $4 Price Target from Roth Capital
TL;DR
HeartBeam's FDA-pending 12-lead ECG device offers investors a first-mover advantage in remote cardiac monitoring with projected $20M revenue by 2028 and 70% gross margins.
HeartBeam's compact device synthesizes 12-lead ECGs using 3D signals with 93.4% diagnostic agreement in clinical studies, pending FDA clearance expected by end of 2025.
HeartBeam's portable ECG technology enables early cardiac detection outside medical facilities, improving access to care and potentially saving lives through decentralized monitoring.
HeartBeam created a credit card-sized device that generates full 12-lead ECGs wirelessly, revolutionizing how heart conditions are detected in everyday environments.
Found this article helpful?
Share it with your network and spread the knowledge!
HeartBeam Inc. (NASDAQ: BEAT) has been initiated with a Buy rating and $4 price target by Roth Capital Partners, which highlighted the company's groundbreaking 12-lead ECG synthesis software and its potential to transform remote cardiac monitoring.
Roth Capital views HeartBeam as undervalued given its strong clinical validation, lean cost structure, breakthrough technology in remote cardiac monitoring, and potential to redefine how arrhythmias are detected and treated in decentralized care environments.
HeartBeam is creating the first-ever cable-free, credit card-sized device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a full 12-lead ECG for remote cardiac monitoring.
FDA clearance for the 12-lead ECG synthesis software is anticipated by the end of 2025, which would enable a targeted commercial rollout in concierge and preventive cardiology markets.
The pivotal VALID-ECG study (n=198) demonstrated a 93.4% diagnostic agreement between HeartBeam's synthesized ECG and standard 12-lead systems, supporting reliability in arrhythmia assessment.
Roth Capital projects profitability by 2027 and estimates revenue of $20 million by 2028, supported by 70% gross margins and scalable recurring revenue streams.
Roth Capital compared HeartBeam's valuation potential to precedent transactions such as Preventice Solutions' $1.2 billion acquisition (8x LTM sales) and BioTelemetry's $2.8 billion buyout (6x LTM sales).
HeartBeam has AI-driven diagnostic precision, regulatory readiness, and first-mover advantage in 12-lead remote monitoring, positioning it as a compelling opportunity in the medical technology and digital health sectors.
The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT, and the full Roth Capital report can be viewed at https://ibn.fm/FcW8B.
HeartBeam holds over 20 issued patents related to technology enablement, and its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, with the 12-Lead ECG synthesis software currently under FDA review.
Curated from InvestorBrandNetwork (IBN)
